Earnings Release • Nov 13, 2015
Earnings Release
Open in ViewerOpens in native device viewer
| Informazione Regolamentata n. 0481-59-2015 |
Data/Ora Ricezione 13 Novembre 2015 16:41:36 |
MTA - Star | ||||
|---|---|---|---|---|---|---|
| Societa' | : | El.En. | ||||
| Identificativo Informazione Regolamentata |
: | 65756 | ||||
| Nome utilizzatore | : | ELENN01 - Romagnoli | ||||
| Tipologia | : | IRAG 03; IRAG 07; AVVI 03; AVVI 16 | ||||
| Data/Ora Ricezione | : | 13 Novembre 2015 16:41:36 | ||||
| Data/Ora Inizio Diffusione presunta |
: | 13 Novembre 2015 16:56:36 | ||||
| Oggetto | : | the quarterly financial report as of September 30th, 2015 |
The Board of Directors of El.En. approves | |||
| Testo del comunicato |
Vedi allegato.
IRAG03 IRAG07 AVVI 03 AVVI 16
Press release
Revenue was 156,0 million of euro in strong growth (up 25,2%) EBIT was 16,2 million of euro ( up 53,7%) exceeding 10% on Sales Revenue guidance for the full year 2015 at 210 million of euro with EBIT over 20 million
Main consolidated financial results for the third quarter of 2015 :
Florence, November 13th 2015 – – The Board of Directors of El.En. S.p.A., leader on the laser market and listed on the Star segment of the Italian Stock Exchange, approved today the financial report as of September 30th , 2015, which registered consolidated revenue for 156,0 million of euro up 25,2% on the 124,6 million of euro of the corresponding period in 2014. In the quarter Revenue was 49,1 million of euro, also up on the 44,2 million of euro of the corresponding quarter registering an 11,1% increase.
In the first 9 months of 2015 the Group registered a remarkable increase in Income from operations that was up 53,7% on 2014. Net of 1.5 million of euros one time proceeds booked in 2014 for the patent settlement Palomar/Cynosure, such increase would had been equal to 80%.
We are reporting a performance in operations that confirms our more optimistic forecast as provided at the beginning of the year, and recently improved, a set of financial results that are outstanding in terms of revenue growth and profitability with respect to our competitors.
Both the industrial and medical business areas contribute to the excellent performance of the Group, registering a similar revenue growth rate of roughly 25%. The revenue increase touches all our geographical market areas; growth was very strong on the extra European markets, particularly on the US market, and was stronger in Italy than in the rest of Europe.
The improved economic situation in the European region, together with a good absorption of our international markets have allowed the group to grab the advantages deriving from its strong competitive positioning based on continuous technological innovation, and to register notable growths in sales and profits from operations, above the market average of the period.
Gross margin for the nine months was 70,2 million of euro up on the 57,3 million of euro as of September 30th, 2014 due to the strong increase in sales albeit a small inflection in margins on sales margins down to 45,0% from 46,0% of the same period of 2014 as an effect of a less favorable mix and decreased grants for R&D received in the period.
EBITDA for the first nine months was positive for 19,3 million of euro up 61,4% on the 11,9 million of euro as of September 2014. The cost for employees was 30,1 million of euro up 10,9% on the 27,2 million of the corresponding period of the previous year, but improved its productivity as an effect of sales growth, reducing its impact on revenue from 21,8% to 19,3%.
EBIT at the end of the first nine months of 2015 was positive for 16,2 million of euro up 53,7% on the 10,5 million of euro as of September 30th, 2014. EBIT margin on sales was 10,4% up on the 8,5% as of September 2014. Net of the on time proceeds stemming from the Palomar/Cynosure patent settlement (1,5 million of euro) registered in 2014, EBIT would have marked an even stronger increase, equal to roughly 80%.
Income before taxes for the 9 months was equal to 17,2 million of euro up from the 18,7 million of euro of the same period in 2014. Also this result needs to be interpreted segregating the extraordinary and one time proceeds of 2014 for a total of roughly 9 million of euro – due to the Palomar settlement (1,5 million of euro), to the gain on the sale of Cynosure shares (4,5 million of euro) and to the higher foreign exchange financial gains (roughly 3 million of euro). Net of such entries the pre tax income for the first 9 months of 2015 would have exceeded 2014's income by roughly 7 million of euro.
The Net financial position of the Group decreases for roughly 24,0 million of euro from December 2014, and stayed positive for 23,1 million of euro. The decrease is related as of 10,5 million of euro to temporary investments of liquidity, that for their nature can't be booked within current assets and therefore within the net financial position; moreover, the group paid in the period roughly 5 million in dividends and invested 5 million of euro in fixed assets.
As an effect of the increasingly favorable economic environment and of the ability of the group to exploit the growth opportunities that the markets are offering, also the third quarter of 2015 showed brilliant financial results, exceeding the guidance provided at the beginning of the year. The group therefore confirms it expects to exceed 210 million of revenue and 20 million of EBIT for the full year
The manager in charge of preparing the corporate accounting records, Enrico Romagnoli, declares, pursuant to paragraph 2, article 154-bis of the Consolidated Finance Law, that the accounting disclosures provided in this document correspond to the accounting records, books and entries.
As required by Consob, the Quarterly report as of September 30th, 2015 will be available for the public at our premises in Calenzano, at Borsa Italiana SpA, on our website www.elengroup.com (section "Investor Relations / Relazioni e Bilanci") and on authorized storage website from November 13th , 2015.
Tuesday November 17th 2015, at 3.00pm CET, (2:00 GMT) (9.00am EST) a conference call will be held with the financial community during which the Group's economic and financial results will be discussed. It will be possible to connect to the call by dialing the following numbers: from Italy + 39 02 8020911, from UK +44 1212818004, from USA +1 7187058796.
The presentation slides can be downloaded before the conference call from the Investor Relations page on EL.EN. web site: http://www.elengroup.com/it/investor-relations/presentazioni
El.En., an Italian company, is the parent of a high-.tech industrial group operating in the optoelectronics sector. Based on proprietary technology and multidisciplinary know-how, the El.En Group manufactures laser sources (gas, semiconductor, solid-state and liquid) and innovative laser systems for medical and industrial applications. The El.En. Group is the laser market leader in Italy and among the top operators in Europe. It designs, manufactures and sells worldwide:
- Medical laser equipment used in dermatology, cosmetics, physiotherapy, dentistry and gynecology;
- Industrial laser systems for applications ranging from cutting, marking and welding metals, wood, plastic and glass to decorating leather and textiles and restoring/conserving artwork;
- Laser systems for scientific research
EL.EN has been listed on the Star (MTA) of Borsa Italiana. Its market floatation is approximately 42% and its market capitalization amounts to Euro 216,9 million.
Cod. ISIN: IT0001481867 Code: ELN Listed on MTA Mkt capt.: 216,9 mln/Euro Cod. Reuters: ELN.MI Cod. Bloomberg: ELN IM
For further information:
El.En. SpA Polytems HIR Polytems HIR Enrico ROMAGNOLI Silvia ADRIANI Bianca FERSINI MASTELLONI Investor Relations Manager Press Office Financial Communication [email protected] [email protected] [email protected]
Tel. +39-055-8826807 Tel.+39/066797849–0669923324 Tel.+39/066797849–0669923324
| Income Statement - 3 months | 30/09/15 | Inc.% | 30/09/14 | Inc.% | Var.% |
|---|---|---|---|---|---|
| Revenues | 49.122 | 100,0% | 44.218 | 100,0% | 11,1% |
| Change in inventory of finished goods and WIP | 2.131 | 4,3% | 1.244 | 2,8% | 71,4% |
| Other revenues and income | 812 | 1,7% | 367 | 0,8% | 121,0% |
| Value of production | 52.065 | 106,0% | 45.829 | 103,6% | 13,6% |
| Purchase of raw materials | 27.799 | 56,6% | 23.043 | 52,1% | 20,6% |
| Change in inventory of raw material | (1.786) | -3,6% | 530 | 1,2% | |
| Other direct services | 3.894 | 7,9% | 3.041 | 6,9% | 28,0% |
| Gross margin | 22.159 | 45,1% | 19.215 | 43,5% | 15,3% |
| Other operating services and charges | 6.147 | 12,5% | 5.623 | 12,7% | 9,3% |
| Added value | 16.012 | 32,6% | 13.593 | 30,7% | 17,8% |
| For staff costs | 9.231 | 18,8% | 8.674 | 19,6% | 6,4% |
| EBITDA | 6.781 | 13,8% | 4.919 | 11,1% | 37,9% |
| Depreciation, amortization and other accruals | 962 | 2,0% | 871 | 2,0% | 10,5% |
| EBIT | 5.819 | 11,8% | 4.048 | 9,2% | 43,7% |
| Net financial income (charges) | (341) | -0,7% | 3.370 | 7,6% | |
| Share of profit of associated companies | 18 | 0,0% | (13) | -0,0% | |
| Other Income (expense) net | 0 | 0,0% | (21) | -0,0% | |
| Income (loss) before taxes | 5.496 | 11,2% | 7.385 | 16,7% | -25,6% |
| Income Statement | 30/09/15 | Inc.% | 30/09/14 | Inc.% | Var.% |
|---|---|---|---|---|---|
| Revenues | 156.006 | 100,0% | 124.616 | 100,0% | 25,2% |
| Change in inventory of finished goods and WIP | 3.754 | 2,4% | 5.067 | 4,1% | -25,9% |
| Other revenues and income | 1.773 | 1,1% | 1.644 | 1,3% | 7,9% |
| Value of production | 161.533 | 103,5% | 131.327 | 105,4% | 23,0% |
| Purchase of raw materials | 87.049 | 55,8% | 64.822 | 52,0% | 34,3% |
| Change in inventory of raw material | (7.523) | -4,8% | (489) | -0,4% | 1439,1% |
| Other direct services | 11.772 | 7,5% | 9.719 | 7,8% | 21,1% |
| Gross margin | 70.236 | 45,0% | 57.274 | 46,0% | 22,6% |
| Other operating services and charges | 20.789 | 13,3% | 18.141 | 14,6% | 14,6% |
| Added value | 49.446 | 31,7% | 39.132 | 31,4% | 26,4% |
| For staff costs | 30.136 | 19,3% | 27.169 | 21,8% | 10,9% |
| EBITDA | 19.310 | 12,4% | 11.964 | 9,6% | 61,4% |
| Depreciation, amortization and other accruals | 3.117 | 2,0% | 1.432 | 1,1% | 117,8% |
| EBIT | 16.193 | 10,4% | 10.532 | 8,5% | 53,7% |
| Net financial income (charges) | 881 | 0,6% | 3.795 | 3,0% | -76,8% |
| Share of profit of associated companies | 117 | 0,1% | (13) | -0,0% | |
| Other net income (expense) | 0 | 0,0% | 4.430 | 3,6% | |
| Income (loss) before taxes | 17.191 | 11,0% | 18.744 | 15,0% | -8,3% |
In accordance with the recommendation CESR/05-178b on alternative performance indicators, the Group uses, in addition to the financial information required by IFRS, some information derived from the latter, although not required by IFRS (non - GAAP measures). These are presented in order to allow a better assessment of the performance and the management of the group and should not be considered as alternatives to those required by IFRS.
The Group uses the following alternative performance indicators to evaluate the financial performance:
The Group uses as alternative performance indicators to evaluate their ability to cope with financial obligations:
The alternative performance measures are used by the Issuer to monitor and evaluate the performance of the group and are not defined as accounting measures either within Italian GAAP or the IAS / IFRS. Therefore, the criteria used by the Group may not be consistent with those adopted by other operators and / or groups and therefore may not be comparable.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.